Editas Medicine, Inc. (EDIT) News

Editas Medicine, Inc. (EDIT): $62.07

2.96 (+5.01%)

POWR Rating

Component Grades













Add EDIT to Watchlist
Sign Up

Industry: Biotech


of 505

in industry

Filter EDIT News Items

EDIT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

EDIT News Highlights

  • EDIT's 30 day story count now stands at 10.
  • Over the past 21 days, the trend for EDIT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • EMMA, AADI and CASI are the most mentioned tickers in articles about EDIT.

Latest EDIT News From Around the Web

Below are the latest news stories about Editas Medicine Inc that investors may wish to consider to help them evaluate EDIT as an investment opportunity.

7 Gene Editing Stocks Promising to Change our DNA

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market.

Chris Markoch on InvestorPlace | September 15, 2021

Aadi Bioscience Appoints Emma Reeve to its Board of Directors

LOS ANGELES, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Emma Reeve to its Board of Directors as Audit Committee Chair. Ms. Reeve brings over 25 years of value creation in pharmaceutical, medical device and bio-pharma service companies and a successful track record of transitioni

Yahoo | September 13, 2021

3 Red-Hot Healthcare Stocks to Buy in September

There is no shortage of stocks making big gains. Jason Hawthorne (Danaher): Danaher has been widely recognized for its operational excellence and decentralized model. In fact, its Danaher Business System was profiled in the Harvard Business Review in 2015.

Yahoo | September 9, 2021

Editas Medicine Names Emma Reeve to Board of Directors

Emma Reeve Editas Medicine today announced that it has appointed Emma Reeve to its Board of Directors. CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Emma Reeve to its Board of Directors. Ms. Reeve is an accomplished biopharmaceutical executive with more than 25 years of global financial experience across pharmaceutical, medical device, and bio-pharma companies. Most recently, Ms.

Yahoo | September 8, 2021

Initial Clinical Data from Editas Medicine’s BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September

Data to include patient safety assessments and a preliminary analysis of secondary endpoints to evaluate biological activity Abstract selected for oral presentation on September 29 Company to host webcast investor event following the presentation on September 29 at 11:00 a.m. ET CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that an abstract featuring initial clinical data from the BRILLIANCE clinical t

Yahoo | September 7, 2021

Forget About the Genomic Revolution, the Proteomic Revolution Is Coming

Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.

Luke Lango on InvestorPlace | September 3, 2021

Why Is Editas (EDIT) Up 33.8% Since Last Earnings Report?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 3, 2021

Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences: Wells Fargo 2021 Virtual Healthcare ConferenceFireside Chat (Virtual)Date: Friday, September 10, 2021Time: 8:00 a.m. ET Morgan Stanley 19th Annual Global Healthcare ConferenceFireside Chat (Virtual)Date: Tuesday, September 14, 2021Time: 9:30 a.m. ET The events will be webcast l

Yahoo | September 2, 2021

Is Editas Medicine (NASDAQ:EDIT) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Yahoo | September 1, 2021

Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today

Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology.

Chris MacDonald on InvestorPlace | August 23, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 4.2507 seconds.